Mannkind Corp (MNKD)

Overview News Price History Option Chain Why MNKD Down? Discussions Forecast Stock Split

Mannkind Corp stock is currently priced at $4.18, with a 24-hour trading volume of 1.76M. It has seen a +2.45% increased in the last 24 hours and a -10.49% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.12 pivot point. If it approaches the $4.18 resistance level, significant changes may occur.

Mannkind Corp Stock (MNKD) Financials Data

Mannkind Corp (MNKD) Revenue 2024

MNKD reported a revenue (TTM) of $198.96 million for the quarter ending December 31, 2023, a +99.42% rise year-over-year.

Mannkind Corp (MNKD) Net Income 2024

MNKD net income (TTM) was -$11.94 million for the quarter ending December 31, 2023, a +86.34% increase year-over-year.

Mannkind Corp (MNKD) Cash Flow 2024

MNKD recorded a free cash flow (TTM) of -$8.35 million for the quarter ending December 31, 2023, a +90.54% increase year-over-year.

Mannkind Corp (MNKD) Earnings per Share 2024

MNKD earnings per share (TTM) was -$0.04 for the quarter ending December 31, 2023, a +88.24% growth year-over-year.

Mannkind Corp Stock (MNKD) Latest News

MannKind Repays Certain Debt Obligations

GlobeNewswire Inc.

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research

MannKind Announces CFO Transition

GlobeNewswire Inc.

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

Benzinga

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

GlobeNewswire Inc.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Initiated	Wedbush: Outperform	Oct-10-23
Initiated	RBC Capital Mkts: Sector Perform	May-14-21
Initiated	Oppenheimer: Outperform	Dec-24-19
Initiated	Cantor Fitzgerald: Overweight	Oct-25-19
Initiated	BTIG Research: Buy	May-14-19
Initiated	SVB Leerink: Outperform	Mar-04-19
Initiated	SVB Leerink: Outperform	Feb-22-19
Downgrade	Maxim Group: Hold → Sell	Feb-28-18
Downgrade	Maxim Group: Buy → Hold	Nov-01-17
Initiated	H.C. Wainwright: Buy	Oct-10-17
Reiterated	Maxim Group: Buy	Oct-06-17
Initiated	Maxim Group: Buy	Aug-11-17
Reiterated	Piper Jaffray: Underweight	May-10-16
Reiterated	RBC Capital Mkts: Underperform	May-10-16
Reiterated	Piper Jaffray: Underweight	Jan-06-16
Reiterated	RBC Capital Mkts: Underperform	Jan-06-16
Downgrade	RBC Capital Mkts: Outperform → Underperform	Nov-04-15
Downgrade	Piper Jaffray: Neutral → Underweight	Sep-09-15
Reiterated	RBC Capital Mkts: Outperform	Aug-03-15
Downgrade	JP Morgan: Neutral → Underweight	May-11-15
Reiterated	MLV & Co: Hold	May-11-15
Reiterated	RBC Capital Mkts: Outperform	Apr-16-15